Related references
Note: Only part of the references are listed.In vitro inhibition and induction of human liver cytochrome P450 enzymes by a novel anti-fibrotic drug fluorofenidone
Linling Li et al.
XENOBIOTICA (2021)
Fluorofenidone attenuates renal fibrosis by inhibiting the mtROS-NLRP3 pathway in a murine model of folic acid nephropathy
Xiaohua Liao et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)
Fluorofenidone Alleviates Renal Fibrosis by Inhibiting Necroptosis Through RIPK3/MLKL Pathway
Qin Dai et al.
FRONTIERS IN PHARMACOLOGY (2020)
Current advances in idiopathic pulmonary fibrosis: the pathogenesis, therapeutic strategies and candidate molecules
Meng Lv et al.
FUTURE MEDICINAL CHEMISTRY (2019)
The Protective Effect of Fluorofenidone against Cyclosporine A-Induced Nephrotoxicity
Yang Chen et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2019)
Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets
Yi-Min Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Spermidine-mediated poly(lactic-co-glycolic acid) nanoparticles containing fluorofenidone for the treatment of idiopathic pulmonary fibrosis
Jing Tang et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2017)
The Protective Mechanism of Fluorofenidone in Renal Interstitial Inflammation and Fibrosis
Yiting Tang et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2015)
Synthesis and structure-activity relationship of 5-substituent-2(1H)-pyridone derivatives as anti-fibrosis agents
Jun Chen et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Determination of AKF-PD in whole blood of rat by HPLC-UV
W Cao et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2006)
Share Paper
